Assessing Efficacy and Safety: Oxytocin Monotherapy vs. Oxytocin + Carbetocin Combination Therapy

Year : 2024 | Volume :01 | Issue : 01 | Page : 40-51
By

Mohammad Kaif A. Mansuri

Vishwa J. Mehta

Abstract

Objective: Comparing the Effectiveness between Oxytocin monotherapy and Oxytocin + Carbetocin. Methods: A prospective, non-randomized, observational study focusing on 221 women with CS was conducted. The patients eligible based on inclusion and exclusion criteria were screened and final sample size was 139. Individual patient data including patient demographics, medical history, OT notes, pre and post CBC reports, and safety data were obtained from the patient records. The study compared between Oxytocin monotherapy which included 67 patients and Oxytocin + carbetocin combination which has 72 pateints. The desired outcome was to compare blood loss, Hb, HCT and the administration of the treatment in preexisting conditions. Results: The incidence of blood loss was higher in Oxytocin monotherapy compared to oxytocin + carbetocin (421.94 ± 120.48 vs 356.25 ± 116.89; P=0.0003) suggesting that addition of carbetocin reduces blood loss and reduces the risk of PPH. The decline in Hb (P=0.16) and HCT (P=0.27) levels between the treatment groups did not show any discernible differences. The Administration of Oxytocin + carbetocin was slightly higher in PIH patients (53.48%) compared to Oxytocin monotherapy (34.88%), however there was no significant difference determined (P=). Also there was no difference in the usage of this treatment groups in Anaemic patients. Conclusion: There was a significant reduction in blood loss when carbetocin was added in the treatment regimen. However it has no effect on the Hb and HCT levels and its increase in utilization in pre-exsiting conditions suggesting no significant difference.

Keywords: Blood loss, PPH, HB, CS, oxytocin, carbetocin

[This article belongs to International Journal of Tropical Medicines(ijtm)]

How to cite this article: Mohammad Kaif A. Mansuri, Vishwa J. Mehta. Assessing Efficacy and Safety: Oxytocin Monotherapy vs. Oxytocin + Carbetocin Combination Therapy. International Journal of Tropical Medicines. 2024; 01(01):40-51.
How to cite this URL: Mohammad Kaif A. Mansuri, Vishwa J. Mehta. Assessing Efficacy and Safety: Oxytocin Monotherapy vs. Oxytocin + Carbetocin Combination Therapy. International Journal of Tropical Medicines. 2024; 01(01):40-51. Available from: https://journals.stmjournals.com/ijtm/article=2024/view=144898

References

  1. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet (London, England). 2006;367(9516):1066-74.
  2. Bazirete O, Nzayirambaho M, Umubyeyi A, Karangwa I, Evans M. Risk factors for postpartum haemorrhage in the Northern Province of Rwanda: A case control study. PloS one. 2022;17(2):e0263731.
  3. Rogers J, Wood J, McCandlish R, Ayers S, Truesdale A, Elbourne D. Active versus expectant management of third stage of labour: the Hinchingbrooke randomised controlled trial. Lancet (London, England). 1998;351(9104):693-9.
  4. Oyelese Y, Ananth CV. Postpartum hemorrhage: epidemiology, risk factors, and causes. Clinical obstetrics and gynecology. 2010;53(1):147-56.
  5. Stones RW, Paterson CM, Saunders NJ. Risk factors for major obstetric haemorrhage. European journal of obstetrics, gynecology, and reproductive biology. 1993;48(1):15-8.
  6. Weeks AD, Mirembe FM. The retained placenta-new insights into an old problem. European journal of obstetrics, gynecology, and reproductive biology. 2002;102(2):109-10.
  7. Silver RM, Major H. Maternal coagulation disorders and postpartum hemorrhage. Clinical obstetrics and gynecology. 2010;53(1):252-64.
  8. Mousa HA, Blum J, Abou El Senoun G, Shakur H, Alfirevic Z. Treatment for primary postpartum haemorrhage. The Cochrane database of systematic reviews. 2014;2014(2):Cd003249.
  9. Miller S, Fathalla MMF, Youssif MM, Turan J, Camlin C, Al-Hussaini TK, et al. A comparative study of the non-pneumatic anti-shock garment for the treatment of obstetric hemorrhage in Egypt. 2010;109(1):20-4.
  10. Maughan KL, Heim SW, Galazka SS. Preventing postpartum hemorrhage: managing the third stage of labor. American family physician. 2006;73(6):1025-8.
  11. Salati JA, Leathersich SJ, Williams MJ, Cuthbert A, Tolosa JE. Prophylactic oxytocin for the third stage of labour to prevent postpartum haemorrhage. The Cochrane database of systematic reviews. 2019;4(4):Cd001808.
  12. Hofmeyr GJ, Mshweshwe NT, Gülmezoglu AM. Controlled cord traction for the third stage of labour. The Cochrane database of systematic reviews. 2015;1(1):Cd008020.
  13. Vogel JP, Williams M, Gallos I, Althabe F, Oladapo OT. WHO recommendations on uterotonics for postpartum haemorrhage prevention: what works, and which one? BMJ global health. 2019;4(2):e001466.
  14. Kota SK, Gayatri K, Jammula S, Kota SK, Krishna SV, Meher LK, et al. Endocrinology of parturition. Indian journal of endocrinology and metabolism. 2013;17(1):50-9.
  15. Larciprete G, Montagnoli C, Frigo M, Panetta V, Todde C, Zuppani B, et al. Carbetocin versus oxytocin in caesarean section with high risk of post-partum haemorrhage. Journal of prenatal medicine. 2013;7(1):12-8.
  16. Jones AJ, Federspiel JJ, Eke AC. Preventing postpartum hemorrhage with combined therapy rather than oxytocin alone. American journal of obstetrics & gynecology MFM. 2023;5(2s):100731.
  17. Fernando D, Siederer S, Singh S, Schneider I, Gupta A, Powell M, et al. Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin Administered via an Inhaled Route in Healthy Females: Randomized, Single-blind, Phase 1 Study. EBioMedicine. 2017;22:249-55.
  18. Diop A, Daff B, Sow M, Blum J, Diagne M, Sloan NL, et al. Oxytocin via Uniject (a prefilled single-use injection) versus oral misoprostol for prevention of postpartum haemorrhage at the community level: a cluster-randomised controlled trial. The Lancet Global health. 2016;4(1):e37-44.
  19. Pileggi-Castro C, Nogueira-Pileggi V, Tunçalp Ö, Oladapo OT, Vogel JP, Souza JP. Non-pneumatic anti-shock garment for improving maternal survival following severe postpartum haemorrhage: a systematic review. Reproductive health. 2015;12:28.
  20. Attilakos G, Psaroudakis D, Ash J, Buchanan R, Winter C, Donald F, et al. Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double-blind randomised trial. BJOG : an international journal of obstetrics and gynaecology. 2010;117(8):929-36.
  21. Borruto F, Treisser A, Comparetto C. Utilization of carbetocin for prevention of postpartum hemorrhage after cesarean section: a randomized clinical trial. Archives of gynecology and obstetrics. 2009;280(5):707-12.
  22. Wormer KC, Jamil RT, Bryant SB. Acute Postpartum Hemorrhage. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Radia Jamil declares no relevant financial relationships with ineligible companies. Disclosure: Suzanne Bryant declares no relevant financial relationships with ineligible companies.: StatPearls Publishing Copyright © 2024, StatPearls Publishing LLC.; 2024.
  23. Angolile CM, Max BL, Mushemba J, Mashauri HL. Global increased cesarean section rates and public health implications: A call to action. Health science reports. 2023;6(5):e1274.
  24. Cegolon L, Mastrangelo G, Maso G, Dal Pozzo G, Ronfani L, Cegolon A, et al. Understanding Factors Leading to Primary Cesarean Section and Vaginal Birth After Cesarean Delivery in the Friuli-Venezia Giulia Region (North-Eastern Italy), 2005-2015. Scientific reports. 2020;10(1):380.
  25. Alkema L, Chou D, Hogan D, Zhang S, Moller AB, Gemmill A, et al. Global, regional, and national levels and trends in maternal mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Maternal Mortality Estimation Inter-Agency Group. Lancet (London, England). 2016;387(10017):462-74.
  26. Mannaerts D, Van der Veeken L, Coppejans H, Jacquemyn Y. Adverse Effects of Carbetocin versus Oxytocin in the Prevention of Postpartum Haemorrhage after Caesarean Section: A Randomized Controlled Trial. Journal of pregnancy. 2018;2018:1374150.
  27. Esseissah SA, Mohamed HI, Elnoury MA, Ali AN. Efficacy of Carbetocin versus Oxytocin and Ergometrin in Prevention of Postpartum Hemorrhage after Cesarean Section %J Benha Journal of Applied Sciences. 2022;7(1):109-15.
  28. Voon HY, Suharjono HN, Shafie AA, Bujang MA. Carbetocin versus oxytocin for the prevention of postpartum hemorrhage: A meta-analysis of randomized controlled trials in cesarean deliveries. Taiwanese Journal of Obstetrics and Gynecology. 2018;57(3):332-9.
  29. El Behery MM, El Sayed GA, El Hameed AA, Soliman BS, Abdelsalam WA, Bahaa A. Carbetocin versus oxytocin for prevention of postpartum hemorrhage in obese nulliparous women undergoing emergency cesarean delivery. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2016;29(8):1257-60.
  30. Jin XH, Li D, Li X. Carbetocin vs oxytocin for prevention of postpartum hemorrhage after vaginal delivery: A meta-analysis. Medicine. 2019;98(47):e17911.
Regular Issue Subscription Original Research
Volume 01
Issue 01
Received April 1, 2024
Accepted April 8, 2024
Published May 3, 2024
Views: 55